# Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

> **NCT03695471** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 9 (actual)

## Conditions studied

- Mycosis Fungoides
- Sezary Syndrome
- Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03695471
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-04
- **Primary completion:** 2023-06-21
- **Final completion:** 2024-10-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03695471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03695471, "Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03695471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*